KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Accounts Payables (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Accounts Payables for 15 consecutive years, with $24.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accounts Payables rose 5.38% year-over-year to $24.8 million, compared with a TTM value of $24.8 million through Dec 2025, up 5.38%, and an annual FY2025 reading of $24.8 million, up 5.38% over the prior year.
  • Accounts Payables was $24.8 million for Q4 2025 at Travere Therapeutics, up from $18.2 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $41.7 million in Q4 2023 and bottomed at $5.8 million in Q3 2021.
  • Average Accounts Payables over 5 years is $18.8 million, with a median of $17.8 million recorded in 2022.
  • The sharpest move saw Accounts Payables surged 141.04% in 2023, then tumbled 43.53% in 2024.
  • Year by year, Accounts Payables stood at $15.1 million in 2021, then increased by 14.17% to $17.3 million in 2022, then soared by 141.04% to $41.7 million in 2023, then crashed by 43.53% to $23.5 million in 2024, then grew by 5.38% to $24.8 million in 2025.
  • Business Quant data shows Accounts Payables for TVTX at $24.8 million in Q4 2025, $18.2 million in Q3 2025, and $19.1 million in Q2 2025.